229 related articles for article (PubMed ID: 16289173)
1. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
2. The androgen receptor and prostate cancer invasion.
Bonaccorsi L; Muratori M; Marchiani S; Forti G; Baldi E
Mol Cell Endocrinol; 2006 Feb; 246(1-2):157-62. PubMed ID: 16376012
[TBL] [Abstract][Full Text] [Related]
3. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines.
Bonaccorsi L; Nosi D; Muratori M; Formigli L; Forti G; Baldi E
J Mol Endocrinol; 2007 Feb; 38(1-2):51-66. PubMed ID: 17242169
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer: a model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model.
Bonaccorsi L; Nosi D; Quercioli F; Formigli L; Zecchi S; Maggi M; Forti G; Baldi E
Steroids; 2008 Oct; 73(9-10):1030-7. PubMed ID: 18358509
[TBL] [Abstract][Full Text] [Related]
5. Signaling mechanisms that mediate invasion in prostate cancer cells.
Bonaccorsi L; Marchiani S; Muratori M; Carloni V; Forti G; Baldi E
Ann N Y Acad Sci; 2004 Dec; 1028():283-8. PubMed ID: 15650253
[TBL] [Abstract][Full Text] [Related]
6. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR).
Bonaccorsi L; Carloni V; Muratori M; Formigli L; Zecchi S; Forti G; Baldi E
Int J Cancer; 2004 Oct; 112(1):78-86. PubMed ID: 15305378
[TBL] [Abstract][Full Text] [Related]
7. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor.
Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB
Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741
[TBL] [Abstract][Full Text] [Related]
8. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells.
Bonaccorsi L; Muratori M; Carloni V; Marchiani S; Formigli L; Forti G; Baldi E
Steroids; 2004 Aug; 69(8-9):549-52. PubMed ID: 15288768
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
10. Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3.
Murthy S; Marcelli M; Weigel NL
Prostate; 2003 Sep; 56(4):293-304. PubMed ID: 12858358
[TBL] [Abstract][Full Text] [Related]
11. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells.
Marchiani S; Bonaccorsi L; Ferruzzi P; Crescioli C; Muratori M; Adorini L; Forti G; Maggi M; Baldi E
J Cancer Res Clin Oncol; 2006 Jun; 132(6):408-16. PubMed ID: 16485114
[TBL] [Abstract][Full Text] [Related]
12. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
13. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
14. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
Bao BY; Hu YC; Ting HJ; Lee YF
Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor and prostate cancer invasion.
Bonaccorsi L; Muratori M; Carloni V; Zecchi S; Formigli L; Forti G; Baldi E
Int J Androl; 2003 Feb; 26(1):21-5. PubMed ID: 12534934
[TBL] [Abstract][Full Text] [Related]
16. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
18. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
19. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
20. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy.
Xu XF; Zhou SW; Zhang X; Ye ZQ; Zhang JH; Ma X; Zheng T; Li HZ
Asian J Androl; 2006 Jul; 8(4):455-62. PubMed ID: 16763722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]